---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-024587"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2022-09-08T23:59:59+00:00"
generated_at: "2026-06-23T13:20:41.849586+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q1 record revenue $13.7M (+22% YoY); adjusted EBITDA $450K

## Summary
- Record quarterly revenue $13.7M, up 22% from $11.3M in prior year quarter.
- Adjusted EBITDA $450K vs $422K; operating loss $284K includes $206K stock comp and $528K D&A.
- Gross margin 49% vs 52% due to higher study expenses and SaaS costs; bookings at record level.
- Cash $8.1M, no debt; net cash used in ops $195K, investing $754K for lab equipment.
- Alloy Therapeutics partnership delivered series of antibody hits.

## SEC filing metadata
- accession: 0001628280-22-024587
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2022-09-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828022024587/0001628280-22-024587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828022024587/csbr-20220908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-024587
- JSON: https://secwatch.observer/filing/0001628280-22-024587.json
- Plain text: https://secwatch.observer/filing/0001628280-22-024587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.